InsiderTrades

Form 4 for TARS Tarsus Pharmaceuticals, Inc.

Accepted 2025-06-18 00:00:00 ET · period of report 2025-06-16 · accession 0001819790-25-000102 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-06-18 2025-06-16 TARS Farrow Jeffrey S See Remarks M - OptEx — +27.9K 50.3K +124% —
D 2025-06-18 2025-06-17 TARS Farrow Jeffrey S See Remarks S - Sale+OE $40.42 -13.6K 36.7K -27% -$550.0K
D 2025-06-18 2025-06-16 TARS Farrow Jeffrey S See Remarks M - OptEx $0.00 -27.9K 55.8K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-06-16 M A 27,881 — 50,312 D — — (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
2 Common Common Stock 2025-06-17 S D 13,608 $40.42 36,704 D — —
3 Derivative Restricted Stock Units 2025-06-16 M D 27,881 $0.00 55,763 D — · — to — 27,881 Common Stock (F3) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. (F4) RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.